Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 11/2019

01-11-2019 | Fibromatosis | Original Article

Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan

Authors: Yoshihiro Nishida, Akira Kawai, Junya Toguchida, Akira Ogose, Keisuke Ae, Toshiyuki Kunisada, Yoshihiro Matsumoto, Tomoya Matsunobu, Kunihiko Takahashi, Kazuki Nishida, Toshifumi Ozaki

Published in: International Journal of Clinical Oncology | Issue 11/2019

Login to get access

Abstract

Background

Treatment modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative treatment. In this study, tumor characteristics of DF, transition of the treatment modality, and clinical outcome of surgical treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan.

Methods

Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical treatment.

Results

The number of registered patients increased gradually. The frequency of surgical treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34).

Conclusions

The treatment modality has shifted from surgical to conservative treatment, with risk factors for surgical treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
Literature
1.
Kasper B, Ströbel P, Hohenberger P (2011) Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 16:682–693CrossRef
2.
Reitamo JJ, Hayry P, Nykyri E et al (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673CrossRef
3.
Gronchi A, Casali PG, Mariani L et al (2003) Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 21:1390–1397CrossRef
4.
Lev D, Kotilingam D, Wei C et al (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25:1785–1791CrossRef
5.
Merchant NB, Lewis JJ, Woodruff JM et al (1999) Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 86:2045–2052CrossRef
6.
Honeyman JN, Theilen TM, Knowles MA et al (2013) Desmoid fibromatosis in children and adolescents: a conservative approach to management. J Pediatr Surg 48:62–66CrossRef
7.
Bonvalot S, Eldweny H, Haddad V et al (2008) Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 34:462–468CrossRef
8.
Fiore M, Rimareix F, Mariani L et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16:2587–2593CrossRef
9.
ESMO/European Sarcoma Network Working Group (2012) Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):92–99
10.
Dangoor A, Seddon B, Gerrand C et al (2016) UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 6:20CrossRef
11.
Grimer R, Judson I, Peake D, Seddon B (2010) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010:506182PubMedPubMedCentral
12.
Fukushima T, Ogura K, Akiyama T et al (2018) Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. BMC Musculoskelet Disord 19:297CrossRef
13.
Ogura K, Higashi T, Kawai A (2017) Statistics of bone sarcoma in Japan: report from the bone and soft tissue tumor registry in Japan. J Orthop Sci 22:133–143CrossRef
14.
Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553–3558CrossRef
15.
Kawaguchi N, Ahmed AR, Matsumoto S et al (2004) The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 419:165–172CrossRef
16.
Gronchi A, Colombo C, Le Pechoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25:578–583CrossRef
17.
Nishida Y, Tsukushi S, Shido Y et al (2012) Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality. Cancers (Basel) 4:88–99CrossRef
18.
Penel N, Le Cesne A, Bonvalot S et al (2017) Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer 83:125–131CrossRef
19.
Bonvalot S, Desai A, Coppola S et al (2012) The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 23(Suppl 10):x158–x166CrossRef
20.
Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Jt Surg Am 96:631–638CrossRef
21.
Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17:158–167CrossRef
22.
Shido Y, Nishida Y, Nakashima H et al (2009) Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 129:929–933CrossRef
23.
Klein WA, Miller HH, Anderson M, DeCosse JJ (1987) The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863–2868CrossRef
24.
Nishida Y, Tsukushi S, Shido Y et al (2010) Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 28:107–109CrossRef
25.
Hansmann A, Adolph C, Vogel T et al (2004) High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100:612–620CrossRef
26.
Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer 60:1108–1112CrossRef
27.
Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92:1259–1264CrossRef
28.
Nishida Y, Tsukushi S, Urakawa H et al (2015) Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status. Int J Clin Oncol 20:1211–1217CrossRef
29.
Skapek SX, Hawk BJ, Hoffer FA et al (1998) Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 16:3021–3027CrossRef
30.
Crago AM, Denton B, Salas S et al (2013) A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg 258:347–353CrossRef
31.
Peng PD, Hyder O, Mavros MN et al (2012) Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol 19:4036–4042CrossRef
32.
Mullen JT, Delaney TF, Kobayashi WK et al (2012) Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 19:4028–4035CrossRef
33.
Colombo C, Miceli R, Lazar AJ et al (2013) CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 119:3696–3702CrossRef
34.
Domont J, Salas S, Lacroix L et al (2010) High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 102:1032–1036CrossRef
35.
Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518–1527CrossRef
36.
Leithner A, Gapp M, Leithner K et al (2004) Margins in extra-abdominal desmoid tumors: a comparative analysis. J Surg Oncol 86:152–156CrossRef
37.
Le Guellec S, Soubeyran I, Rochaix P et al (2012) CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol 25:1551–1558CrossRef
38.
Nishida Y, Tsukushi S, Urakawa H et al (2016) Simple resection of truncal desmoid tumors: a case series. Oncol Lett 12:1564–1568CrossRef
39.
Hamada S, Futamura N, Ikuta K et al (2014) CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS One 9:e96391CrossRef
Metadata
Title
Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan
Authors
Yoshihiro Nishida
Akira Kawai
Junya Toguchida
Akira Ogose
Keisuke Ae
Toshiyuki Kunisada
Yoshihiro Matsumoto
Tomoya Matsunobu
Kunihiko Takahashi
Kazuki Nishida
Toshifumi Ozaki
Publication date
01-11-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 11/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01512-z

Other articles of this Issue 11/2019

International Journal of Clinical Oncology 11/2019 Go to the issue

Original Article

Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer

Original Article

Including positive lymph node count in the AJCC N staging may be a better predictor of the prognosis of NSCLC patients, especially stage III patients: a large population-based study

Original Article

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Original Article

Efficacy of chemotherapy for older patients with gastric cancer: a multicenter retrospective cohort study

Original Article

PLEKHG5 is a novel prognostic biomarker in glioma patients

Original Article

The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits